NZ573132A - Administration of anti-cd3 antibodies in the treatment of autoimmune diseases - Google Patents

Administration of anti-cd3 antibodies in the treatment of autoimmune diseases

Info

Publication number
NZ573132A
NZ573132A NZ573132A NZ57313207A NZ573132A NZ 573132 A NZ573132 A NZ 573132A NZ 573132 A NZ573132 A NZ 573132A NZ 57313207 A NZ57313207 A NZ 57313207A NZ 573132 A NZ573132 A NZ 573132A
Authority
NZ
New Zealand
Prior art keywords
trx4
day
antibody
administered
amount
Prior art date
Application number
NZ573132A
Other languages
English (en)
Inventor
Paul Ponath
Michael Rosenzweig
Louis Vaickus
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to NZ599379A priority Critical patent/NZ599379A/xx
Publication of NZ573132A publication Critical patent/NZ573132A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ573132A 2006-06-06 2007-06-05 Administration of anti-cd3 antibodies in the treatment of autoimmune diseases NZ573132A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ599379A NZ599379A (en) 2006-06-06 2007-06-05 Administration of anti-cd3 antibodies in the treatment of autoimmune diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44762806A 2006-06-06 2006-06-06
US92148506P 2006-06-06 2006-06-06
PCT/US2007/013232 WO2007145941A2 (en) 2006-06-06 2007-06-05 Administration of anti-cd3 antibodies in the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
NZ573132A true NZ573132A (en) 2012-05-25

Family

ID=38832328

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ573132A NZ573132A (en) 2006-06-06 2007-06-05 Administration of anti-cd3 antibodies in the treatment of autoimmune diseases

Country Status (7)

Country Link
US (1) US20090258001A1 (https=)
EP (2) EP2023955A4 (https=)
JP (1) JP2009539841A (https=)
AU (1) AU2007258694B2 (https=)
CA (1) CA2653387A1 (https=)
NZ (1) NZ573132A (https=)
WO (1) WO2007145941A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
AU2009288354A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
CN105218673A (zh) * 2008-10-10 2016-01-06 新兴产品开发西雅图有限公司 Tcr复合物免疫治疗剂
JP5816164B2 (ja) * 2009-05-07 2015-11-18 ビオメリュー・インコーポレイテッド 抗生物質耐性測定方法
WO2011050104A2 (en) * 2009-10-20 2011-04-28 Tolerx, Inc. Methods of using anti-cd3 antibodies to prevent weight gain
JP2013508392A (ja) * 2009-10-20 2013-03-07 グラクソ グループ リミテッド 自己免疫疾患における抗ｃｄ３抗体の投薬
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN104011207B (zh) 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
SG10201608307WA (en) 2012-04-20 2016-11-29 Emergent Product Dev Seattle Cd3 binding polypeptides
WO2014022841A1 (en) * 2012-08-03 2014-02-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
CN118440206A (zh) 2014-04-07 2024-08-06 中外制药株式会社 免疫活化抗原结合分子
EP3144388B1 (en) 2014-05-13 2020-07-01 Chugai Seiyaku Kabushiki Kaisha T cell-redirecting antigen-binding molecule for cells having immunosuppression function
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US12569477B2 (en) * 2017-06-28 2026-03-10 Mitocholine Ltd Compositions for synergistically enhancing mitochondrial function
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
TW202546002A (zh) * 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
KR20220035369A (ko) * 2019-06-07 2022-03-22 아디맵 엘엘씨 고 친화도 항-cd3 항체, 및 이의 생성 및 사용 방법
EP3984554A4 (en) * 2019-06-11 2023-11-08 ONO Pharmaceutical Co., Ltd. IMMUNOSUPPRESSANT
CR20220049A (es) 2019-07-10 2022-03-02 Chugai Pharmaceutical Co Ltd Moléculas de unión a claudina-6 y usos de las mismas
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658019A (en) 1979-04-26 1987-04-14 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU6642390A (en) * 1989-10-27 1991-05-31 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) * 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) * 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
JP3111024B2 (ja) * 1995-07-19 2000-11-20 キヤノン株式会社 カラーフィルタの製造装置及び製造方法及び表示装置の製造方法及び表示装置を備えた装置の製造方法
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US7041289B1 (en) 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
CA2224256C (en) 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000046750A1 (en) * 1999-02-05 2000-08-10 Samsung Electronics Co., Ltd. Image texture retrieving method and apparatus thereof
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2508264A1 (en) * 2002-12-05 2004-06-24 Protein Design Labs, Inc. Methods of treatment of ulcerative colitis with anti-cd3 antibodies
DE10336334B3 (de) * 2003-08-08 2005-08-04 Cnh Baumaschinen Gmbh Hydraulisches Steuersystem für Baumaschinenen, insbesondere für Bagger
DK1687066T3 (da) * 2003-11-14 2012-11-26 Brigham & Womens Hospital Fremgangsmåder til immunmodulering
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005076965A2 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
JP5139800B2 (ja) * 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
AU2006267090B2 (en) * 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Also Published As

Publication number Publication date
JP2009539841A (ja) 2009-11-19
EP2433650A2 (en) 2012-03-28
WO2007145941A2 (en) 2007-12-21
CA2653387A1 (en) 2007-12-21
WO2007145941A3 (en) 2008-09-25
AU2007258694A1 (en) 2007-12-21
AU2007258694B2 (en) 2011-12-22
EP2023955A4 (en) 2009-10-28
WO2007145941A8 (en) 2008-02-14
EP2433650A3 (en) 2012-12-19
US20090258001A1 (en) 2009-10-15
EP2023955A2 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
AU2007258694B2 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
AU2016200435B2 (en) Anti-ox40 antibodies and methods of using the same
US20200181274A1 (en) Bispecific antibodies that bind cd 123 cd3
EP2609118A2 (en) Anti-ox40 antibodies and methods of using the same
WO2017103003A1 (en) Anti-cd28 humanized antibodies formulated for administration to humans
KR20200128415A (ko) 중증 천식 치료를 위한 항 cd6 항체
AU2020251987A1 (en) Methods of reducing large granular lymphocyte and natural killer cell levels
CN112312971A (zh) 结合cd123和cd3的双特异性抗体的给药
EP4248995A1 (en) Use of anti-ox40 antibody for treating tumors or cancers
KR20210016426A (ko) Cd123 및 cd3에 결합하는 이중특이적 항체의 투약
AU2021352981A1 (en) Anti-cd94 antibodies and methods of use thereof
AU2012201443B2 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2022502380A (ja) 抗ｃｄ１５４抗体の安全な投与を提供する方法
KR20210016332A (ko) 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
CN110546167A (zh) 以抗-cd52抗体治疗多发性硬化症
WO2025231445A1 (en) Methods of using lfa3-fc fusion proteins
HK40050403A (en) Method of providing safe administration of an anti-cd154 antibody
TW202146452A (zh) 結合ｃｄ１２３和ｃｄ３之雙特異性抗體的給藥
KR20210016333A (ko) 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GLAXO GROUP LIMITED, GB

Free format text: OLD OWNER(S): TOLERX, INC.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 JUN 2017 BY THOMSON REUTERS

Effective date: 20140320

LAPS Patent lapsed